rais bar cytogenet test initi
initi coverag bionano genom outperform rate
price target view bngo transit sell optic map
equip research lab clinic diagnost compani posit replac
microarray cytogenet analysi seri clinic valid studi schedul
present confirm saphyr perform well microarray
faster turnaround time believ bngo posit acceler
revenu growth peak cytogenet revenu improv
detect particularli larger variant may possibl saphyr compar
microarray view better analyt perform necessari commerci
success us expect result neg revenu growth
move saphyr research clinic test bngo form
commerci optic map technolog altern long-read
sequenc detect larg genom structur alter earli adopt
focus academ research launch second-gener saphyr
platform offer cost per run view bngo
product profil suitabl high volum clinic diagnost applic
follow path liquid biopsi faster turnaround view valu
proposit cytogenet saphyrfast turnaround time day vs
day microarraysa offer parallel liquid biopsi vs tissue-bas
test solid tumor exampl primari benefit potenti captur
genet inform quickli begin patient best therapi sooner
clinic news drive sale view present data august
cgc meet dr brynn levi columbia critic mileston
support saphyr potenti tool clinic diagnost public
larger valid studi columbia md anderson serv valu
inflect point drive increas clinic test volum begin
healthi lab econom drive sale base current
reimburs model believ lab captur gross margin
cytogenet perform saphyr per chip price price
support gross margin consum bngo sale forecast
assum placement annual consum revenu
headwind expect revenu decreas
strateg shift reagent rental placement model combin
relat restrict wet lab work research center impact report revenu
expect impact trend reced begin
year price histori bngo
bionano commerci saphyr
platform analysi larg structur
variat potenti new market
analyst certif import disclosur see disclosur
view bngo offer research tool
valid clinic applic specif expect
compani transit sell saphyr optic map
platform primarili research lab project requir analysi
larg structur variant busi model focus
consum pull clinic cytogenet lab
view public valid studi columbia
md anderson valu inflect point expect
increas clinic test volum begin
base current assess competit landscap
believ long-read sequenc technolog replic
saphyr perform cost structur digit cytogenet
lab support annual consum revenu
placement saphyr increasingli reagent rental model
rather capit equip split trend
annual test per month per test
improv gross margin begin
contribut cytogenet test outsid us
bngo recogn capit purchas placement
present valid studi demonstr concord
microarray digit cytogenet saphyr aml patient
complet md anderson studi evalu saphyr
cytogenet analysi md patient
public data radboud studi demonstr
feasibl saphyr cytogenet first public eu
new offer saphyr rental contract research market
one cytogenet lab begin use saphyr regular clinic
practic
implement uniqu code simplifi bill saphyr
cytogenet test us
cytogenet variant call rate result materi uptak outsid
long-read sequenc platform adapt support clinic use
cytogenet analysi
lab unabl receiv reimburs saphyr cytogenet
test exist code
system place reagent rental contract fail produc
expect consum pull
us regulatori reform result cytogenet analysi classifi
high risk test requir fda clearanc
pt base ev-to-sal analysi assum multipl estim revenu second full year
cytogenet revenu discount back one year divid million share outstand line peer group
high-growth diagnost compani multipl around due limit scale bngo commerci oper neg cash flow
risk includ clinic accept optic imaging-bas cytogenet test clinic trial risk investigator-sponsor
valid studi saphyr use cytogenet test technolog obsolesc relat current relianc optic imag
assur lab receiv reimburs coverag saphyr use cytogenet test compani like need addit
capit fund oper posit cash flow sale instal laboratori capit equip saphyr may
advers impact macroeconom disloc relat
note see bngo stock trade specul appropri risk toler investor
initi outperform pt
initi coverag bionano genom outperform rate
price target view bngo hybrid busi model transit sell optic
map capit equip academ research lab clinic diagnost compani
posit replac microarray cytogenet analysi view cytogenet
attract market base signific address opportun recur
revenu prior technic failur tradit short- long-read sequenc
technolog cytogenet analysi long turnaround time week
microarray seri clinic valid studi schedul present
confirm saphyr perform well microarray faster turnaround time believ
bngo posit signific acceler revenu growth
peak us cytogenet revenu improv detect particularli
variant larger base pair may possibl saphyr compar
microarray view better analyt perform necessari commerci
success us pt base ev-to-sal analysi assum
multipl estim revenu discount back month
saphyrlow cog support push clinic diagnost
bngo form commerci optic map technolog altern long-
read sequenc platform detect larg genom structur alter earli
adopt focus academ research interest use technolog studi
rare diseas associ larg transloc genom alter
amen next-gener sequenc technolog howev consum pull
per instal unit modest view due limit rang
academ applic rel high cost per run first gener iri platform
focu capit purchas model drive placement base modest adopt
first-gener iri platform domin sequenc franchis
believ life scienc investor written potenti optic map
technolog howev launch second-gener saphyr platform
offer improv informat significantli lower per run cost
view bngo profil suitabl high volum clinic diagnost applic
brynn levi cytogenet data cgc august confirm promis saphyr
view present data august cancer genom consortium cgc
meet dr brynn levi co-author nejm studi establish use
microarray cytogenet analysi critic mileston matur saphyr
potenti tool clinic diagnost specif studi evalu sampl use
saphyr compar karyotyp fish microarray dr levi conclud saphyr
demonstr high level concord size breakpoint genet variant
compar microarray base part strength credibl data present
cgc multipl academ hematolog group includ md anderson mayo clinic
conduct valid studi present
faster turnaround dovetail clinic posit liquid biopsi
view potenti valu proposit cytogenet analysi hematolog
saphyrfast turnaround time less day vs day microarray
potenti superior analyt performancea offer import parallel liquid
biopsi vs tissue-bas test solid tumor exampl primari benefit
potenti captur genet inform quickli begin patient best
therapi sooner liquid biopsi believ oncologist need clinic
outcom studi chang behavior benefit faster treatment decis well
cytogenet market support sale
acknowledg transit microarray optic map saphyr
unlik materi expand size cytogenet market view market
continu enjoy healthi price clear path reimburs coverag
new technolog specif financi model assum lab seek reimburs
cytogenet analysi saphyr exist code
assum lab captur gross margin estim bngo price chip
cytogenet analysi per run support gross margin bngo
consum
view manag assess address market recur revenu
base cytogenet lab revenu per test
test per lab annual peak forecast base
placement annual consum revenu per lab test
annual per lab mention expect cytogenet revenu begin ramp
bngo saphyr pacbio singl molecul real-tim
smrt platform focus larg genom alter captur
short-read sequenc technolog fundament differ practic
believ may overlap platform academ research rare
pediatr diseas howev view date credibl data suggest
long-read sequenc techniqu accur measur clinic relev cytogenet
abnorm view pacbio direct competitor expect
recent termin plan acquisit pacbio impact uptak saphyr
clinic market
howev expect stand-alone pacbio limit financi resourc
invest next-gener technolog expans clinic test menu
view termin transact posit bngo
technolog design analyz larg genom alter addit
intermedi term view erect anti-trust regulatori speed bump limit
market domin like increment improv competit posit
access capit early-stag compani space view broader
ecosystem financi healthi genom analysi compani extend field
potenti acquir bngo optic map technolog
execut commerci build repres potenti risk
addit clinic trial risk associ valid analyt perform saphyr
cytogenet applic view expans reposit commerci
organ primari risk outlook bngo commerci team focus
research-ori academ lab pivot cytogenet compani
call lab affili academ medic center similar institut differ
point contact high volum cancer test lab new call point addit
industrywid shift away capit purchas reagent rental like limit up-front
recogn revenu new clinic account expect
transit year meaning acceler clinic cytogenet revenu
addit technic limit saphyr platform detect
robertsonian transloc use ffpe sampl highli fragment
cfdna often less base pair analyz effect current
optic map technolog view limit relev
research market clinic cytogenet lab
price target share bngo base primarili ev-to-sal
multipl project revenu discount back month
view ev-to-sal appropri methodolog compani transit sustain
profit common valuat metric diagnost test compani
mention view bngo hybrid busi model legaci sale
academ research market potenti futur growth clinic test cytogenet
view pacbio direct publicli trade competitor pacbio
heavili focus academ research market view broad peer group
cancer clinic diagnost compani includ
appropri benchmark valuat howev unlik bngo
compani sell capit equip repres differ profil term
predict revenu growth
highlight exhibit specialti test oncolog lab trade mean
multipl sale vs price target assumpt bngo
factset oppenheim co inc estim
use base year ev-to-sal analysi base expect
bngo need month fulli captur growth potenti cytogenet
market introduct expand us sale forc
sale price-to-sal count back year per bionano genom
last view discount rate appropri bngo given compani limit
instal base instrument clinic lab
view present valid studi data use saphyr cytogent
analysi aml cml md patient quarterli financi metric
import potenti catalyst bngo share clinic trial
investigator-sponsor initi import distinct may limit flexibl
specif time present typic expect result investigator-sponsor
studi present medic meet rather press releas nearli
spring medic meet either postpon cancel due
view june medic meet earliest timelin updat md anderson md
patient columbia variou hematolog malign
bngo believ result radboud univers studi may submit potenti
public visibl timelin potenti public
believ cohort may repres first publish valid larg cytogenet
studi radboud plan enrol leukemia patient constitut
cytogenet aberr larger studi dr levi lab columbia also
expect limit visibl pace enrol
view transit year commerci team focus boost system
placement clinic lab expect vast major placement
reagent rental limit up-front ecnom month valid process
believ current consensu correctli incorpor shift capit purchas
reagent rental placement saphyr estim unit capit
placement reagent rental view current consensu revenu
estim high encourag investor focu unit placement offer
better year-over-year compar revenu revenu estim vs
consensu forecast saphyr placement
due expect headwind relat expect
sustain growth report revenu begin first quarter compar quarter
shift reagent rental model call signfic consum pullthrough
cytogenet lab begin
oppenheim co inc estim compani document
corpor histori busi model
bionano genom form commerci optic imag altern
next-gener sequenc compani base san diego went public
april gross proce unit offer price stock
trade ticker bngo
bngo launch first platform iri academ research market
transit current saphyr platform compar iri saphyr better
throughput faster turnaround time requir less consumm collect
lower cost per sampl
eventtim importancepubl radbound univers cytogenet studi interim data sp anim tissu kit avail earli access anderson md valid univers base cytogenet interim data peopl commerci bngo outperform
take launch saphyr platform lower cost per run
open opportun clinic applic
saphyr platform includ instrument chip consum reagent data
analysi softwar current saphyr larg use academ institut finish
genom fill gap contig left short-read sequenc technolog
take view short-read long-read technolog competit
bngo investig columbia univers md anderson present
data suggest saphyr detect clinic relev larg structur variant
cytogenet analysi saphyr detect genom variant larger base pair
includ balanc transloc variant heterochromat region typic
detect sequenc technolog larger genet variant
common pediatr rare diseas adult aml cll hematolog
malig studi valid concord classic cytogenet assay
saphyr on-going data expect
date bngo instal system saphyr previou system
institut compani current optic map system includ
children hospit philadelphia children nation boston children
garvan institut medic research genentech mcdonnel genom institut
washington univers nation institut pennsylvania state univers
radboud univers medic center salk institut biolog studi
like compani develop genom analyz bngo optic map platform
attract razor-razor blade busi model potenti rel predict
high margin recur revenu demand technolog matur compani sell
two distinct market segment mark differ econom profil
current revenu sale univers academ research institut de
novo sequenc research applic custom typic purchas saphyr
equip outright demand recur revenu reagent kit chip often
variabl date capit purchas equip account major
revenu research market
present analyt valid data cytogenet analysi
expect major futur demand come cytogenet lab pediatr
academ medic center commerci cancer test lab custom
prefer reagent rental structur limit up-front revenu bngo higher per-unit
price chip potenti higher recur revenu run-rate placement
take forecast call vast major revenu cytogenet market come
recur revenu associ chip reagent kit repres
signfic shift prior focu capit equip revenu research market
support better margin time
optic map defin unmet need
optic map high-throughput single-molecul technolog gener order
restrict map high molecular weight genom dna molecul kb
size bngo saphyr optic map often compar long-read singl molecul
real-tim sequenc smrt sequenc sinc singl molecule-bas
order gc-rich repetit dna section
howev technolog fundament differ instead sequenc individu
base saphyr detect fluoresc label site site-specif nick
endonuclease/polymeras repair reaction sometim compar
microfluid sanger sequenc iter sanger sequenc dna fragment
irrevers termin incorpor fluoresc label dideoxi chain-
termin nucleotid produc scaffold fragment base-specif fluoresc
label termin base label base ladder separ capillari array
electrophoresi cae autom label recognit assembl overlap
exhibit present graphic overview saphyr workflow
major approxim two-third human genom made repetit element
singl sequenc repeat segment duplic miscellan heterochromatin
often element longer maximum read length technolog
use input high molecular weight dna rel intact saphyr detect
structur variant short-read even long-read unabl detect high
exhibit breakdown region human dna
cytogenet amen sequenc
technolog deciph mani clinic relev genom
structur short-read input typic prohibit analysi import section genom
percentromer region tandem repeat array cg repeat subtelomer
region studi chromosom structur cytogenet one clinic
applic address sequenc
take capac saphyr order rel long stretch intact dna
singl molecul make technolog conduc clinic cytogenet applic
long-read sequenc
benign patholog chromosom imbal microscop submicroscop
copi number variat cnv genet counsel thoma liehr emphas
crucial role cytogenet play pre- post-nat tumor
diagnost research cytogenet typic studi use spectral karotyp
fluoresc situ hybrid fish compar genom hybrid
cgh exhibit describ three techniqu
exhibit overview current cytogenet assay
assaydescript compar genom hybrid cgh array-compar genom hybrid acgh involv comparison sampl dna specimen refer genom hybrid metaphas chromosom later microarray target sequenc known chromosom karyotyp homolog pair chromosom manipul way distinct colorsspectr karotyp laboratori techniqu detect locat specif dna sequenc chromosom techniqu reli expos chromosom small dna sequenc call probe fluoresc molecul attach fluoresc situ hybrid fish multicolor-fish m-fish parental-origin-determin fish pod-fish bionano genom
variat fish cgh assay includ multicolor-fish parental-origin-
determin fish pod-fish array-bas cgh acgh avail
cytogenet techniqu benefit limit summar exhibit
exhibit benefit limit current cytogenet assay
bridg julia advantag limit cytogenet molecular cytogenet molecular diagnost test mesychym neoplasm
journal orthopaed scienc
euchromat cnv cytognet visibl size mb associ sever
clinic consequ kerhof et al discuss clinic valid copi number
variant detetctionm target next-gener sequenc panel
effect captur potenti deletori chang dna sequenc bp
adequ detect copi number variant cnv singl nulcetotid
polymorph structur rearrang fulli character cancer
abnorm copi number variant structur abnorm need
believ exist technolog cytogenet analysi limit particuarli
regard turnaround time eas use specif fish karotyp
labor-intens furthermor fish specif probe target limit rang
genet coverag microarray-bas cgh improv upon breadth coverag
turnaround time three week longer
take see opportun better detect larg kb rearrang
saphyr acgh technolog clinic relev detect larger
rearrag gener hematolog popul need valid
benefitlimit spectral karotypingpcr may uncoveredpcr may uncoveredpathogenet import genestherapy-induc tumor necrosi overgrowth normal support stromal cell may result false-neg resultinterphas cell prepar ffpe tissu typesor unsatisfactori convent cytogenet fail yield result cryptic rearrang presentanalyz sub-optimal specimenslaboratoriesfish rt-pcrcgh acghinterphas cell prepar ffpe area chromosom screen tool delet duplic and/or amplif locu repres arraymosaicismmay result false-neg mb bngo outperform
saphyr demonstr proof concept cytogenet
cancer genom consortium cgc confer bngo collabor
cytogenetist lead medic research institut columbia medic school
md anderson cancer center discuss potenti applic saphyr
technolog cytogenet oral present entitl optic map role
cytogenom tool cancer see exhibit
exhibit optic map vs karyotyp fish cancer cytogenet
dr levi columbia univers note saphyr potenti streamlin cytogenet
survey result reduct time resourc requir cytogenet analysi
head-to-head comparison describ exhibit dr levi found qualiti
detect compar saphyr a-cgh clinic import abnorm
tcrg region
aim studymethodsblind prospect studi compar result gener optic map result gener routin clinic test clia laboratori use current gold standard cytogenom techniquesestablish clinic diagnost capabl optic map cancer patient aml bionano genom
separ studi present dr kanagal-shamanna md anderson saphyr
detect novel structur variant complex rearrang md patient
detect use technolog fundament saphyr abil map
chromosom fragment larger typic detect rang microarray howev
resolut optic map larger rearrang remain valid
term data present cgc dr kanagal-shamanna sought answer two
question optic map abl detect structur variant identifi soc
assay karyotyp fish microarray optic map provid new
sampl saphyr compar karyotyp detect
aberr compar microarray saphyr detect aberr
dr kanagal-shamanna present two sampl saphyr detect addit
aberr sampl dr kanagal-shamanna note fragment fusion
product detect chromosom map chromosom
exhibit saphyr detect variant captur a-cgh
sampl detect delet chromsom chromosom
fusion encompass genean import variant distinguish aml
exhibit present structur variant detect optic map
exhibit saphyr detect variant captur a-cgh
take see path valid superior variant detect saphyr
expect commerci uptak driven primarili turnaround time lesser degre
valid studi readout
bngo academ collabor current conduct studi readout
mention nearli spring medic meet
either postpon cancel due view june medic meet
earliest timelin updat md anderson md patient columbia variou
bngo believ result radboud univers studi may submit potenti
public visibl timelin potenti public
believ cohort may repres first publish valid larg
cytogenet studi radboud plan enrol leukemia patient
constitut cytogenet aberr larger studi dr levi lab
columbia also expect limit visibl pace enrol
take believ proof-of-concept data variou malign support
posit result on-going valid studi support use constitut disord
clinic applic less matur
defin path reimburs
view inclus optic imaging-bas techniqu practic guidelin import
drive clinic adopt reimburs coverag exist code
cytogenet analysi believ timelin uncertain view
contemporari analog defin path specif view adopt a-cgh
prenat postnat cytogenet analysi offer appropri parallel
take inclus optic imag nccn oncolog treatment
treatment guidelin like take year requir support multi-cent studi
publish top tier medic journal
decemb new england journal medicin nejm publish two larg
multi-cent studi compar chromosom microarray karyotyp sampl
stillbirth prenat sampl collect invas test studi
demonstr potenti chromosom microarray identifi clinic
relev cytogenet variant karyotyp addit studi stillbirth
popul demonstr significantli lower test failur rate chromosom
microarray base result two studi american colleg
obstetrician gynecologist acog societi maternal-fet medicin
smfm publish committe opinion highlight potenti benefit
chromosom microarray test current microarray wide reimburs
cytogenet test deem medic necessari
profession societi recommend use cytogenet
clinic util cytogenet acut leukemia hematolog malign
alreadi recogn key profession societi american societi
hematolog colleg american pathologist cap collabor publish
updat recommend diagnosi acut leukemia guidelin describ
step accur diagnos subtyp leukemia would inform prognosi
treatment option notabl ash-cap guidelin strong recommend
rate use cytogenet test detect certain structur variant
addit morpholog assess pathologist treat clinician
obtain suffici sampl perform convent cytogenet analysi
appropri molecular genet and/or fish test flow cytometr
immunophenotyp flow cytometri panel suffici distinguish
acut leukemia ambigu lineag patient diagnos
acut leukemia molecular genet and/or fish test howev
patient present extramedullari diseas without bone marrow
blood involv pathologist evalu tissu biopsi process
morpholog immunophenotyp cytogenet molecular genet studi
recommend bone marrow ash-cap guidelin
patient confirm mix phenotyp acut leukemia pathologist
treat clinician ensur test
mll transloc perform ash-cap guidelin
american societi clinic oncolog endors ash-cap
guidelin furthermor european societi medic oncolog esmo endors
japanes societi medic oncolog jsmo propos similar guidelin
diagnost work-up aml must includ morpholog peripher blood
bone marrow cytogenet molecular genet assess start
medicar like lead reimburs process
secretari advisori committe genet societi sacgh
form advis reimburs genom test servic emphasi
evidence-bas coverag decisionmak determin test reimburs
recommend cover medicar medicaid reiumburs decion
subsequ inform privat insur well view languag around
reimburs neutral technolog code structur indic
mutat variant test
mention consid sequenc technolog platform
competitor competit analysi focus vendor sell entrench
technolog karotyp fish a-cgh mircoarray exhibit
exhibit overview cytogenet competit landscap
studi entitl valu money array genom hybrid diagnost test
genet caus intellectu disabail regier et al found use array genom
hybrid agh acgh good valu first-lin test option compar
karotyp patient exhibit regier et al provid decision-mak tree
regier et al valu money array genom hybrid diagnost test genet caus intellectu disabl american
journal human genet
sequenc platform competit landscap
exhibit summar current genom technolog platform includ
genom proximo hi-c dovetail genom hi-c view suquenc particuarli
pacbio competit saphyr certain research applic
exhibit overview genom technolog competit landscap
nation center genom analysi support indiana univers
maintain domin market share base eas use low error rate cost
technolog look fill genom inform target
larg accur detect effici technolog though group
genom technolog togeth underli platform technolog vari
short-read smrt-seq nanpor gem sequenc technolog
wherea saphyr hi-c optic map technolog exihibit provid
crude overview cost use platform
take world cost use platform vari wide depend depth
sequenc requir answer clinic scientif interest question
exhibit metric platform
nation center genom analysi support indiana univers
platform read hifi sequel ii half raw data depend machin usual irys/saphyrlow resolut structur data dna molecul length dlsproxim ligat get scaffold inform short read sequencingproximo hi-cnext gem longer read pair genom read pair genom read pair genom minimum read pair soil fecal million cell microbiom tissu blood million cell animal/ hi-c leaf seedl flower tissu plant genom dna must high qualiti prefer longpseudodiploid assembl structur variant call alignmentshort read ngsinexpens short pair read high accuraci variabl fragment often barcod read sequenc high throughputvari dna smrtbell prep concentr per genom scaffold requir input scaffold lower chicago protocol use boost assembl first use hi-c dramat improv assembl proxim ligat get scaffold inform short read read-pair per gigabas haploid genomenanoporelong read sequenc high throughput dna rapid sequenc kit requir pcrup per gbother nextseq miseq hifi ii unknown kit costnanoporebas cost sequenc kit output cell minion/gridion librari prep per genomehi-cflow cell promethion barcod kit bit expensiveunknown estim time/kit/sequenc done dovetailbi request similar sequencingproximo hi-cbi request similar sequencinghi-c prep kit cost two prep microbiom two prep short read ngssmrt seqnext gem librari prep per librari includ size select bioanalyz etc librari prep sequel cell per cell base websit quot best hion minion bngo outperform
saphyr revenu expect
segment revenu model end market separ estim research
market cytogenet research account nearli current revenu
expect cytogenet support major growth begin importantli
expect revenu sever impact disrupt relat term
new saphyr placement consum chip use instal unit
forecast call rebound demand exact time rebound
impact durat public health recommend restrict access
total saphyr revenu estim
respect much step relat return normal
level research market follow sever reduct demand relat
growth estim driven primarili uptak clinic
accord report publish medicar medicaid research review
kandilov et al medicar part payment physician facil total almost
million laboratori test code account total medicar part
 fee-for-servic ff expenditur payment volum laboratori test code
broken laboratori type exhibit acknowledg analysi
date view paper provid good benchmark composit demand
sinc analysi believ consolid physician offic lab market shift
hospit outpati lab result greater concentr
exhibit clinic test reimburs overview laboratori type
medicar medicaid research review kandilov et al
saphyr cytogenet revenu model assum unit placement
cytogenet lab reagent rental basi limit up-front econom
expect acceler cytogenet revenu associ consum chip
unit placement term price forecast assum chip price
capit purchas price saphyr unit
model call cytogenet unit placement annual next
three year total placement end model assum steadi
increas test test per unit test per unit addit
system valid enter gener clinic use total revenu estim
respect
compani report oppenheim co inc estim
saphyr research revenu model assum unit placement
reagent rental basi price assumpt cytogenet marketchip
price capit purchas price saphyr
model call research unit placement annual next three
year total placement end model assum steadi
increas test test per unit test per unit addit
system valid total revenu estim
respect
compani report oppenheim co inc estim
per instal capit chang revenu per revenu per unit cytogenet revenu per cytogenet chang recogn revenu per cytogenet test per saphyr placement new saphyr cytogenet number chip revenu cytogenet test placement revenu cytogenet portion placement capit revenu per instal capit placement revenu cytogenet test revenu growth cytogenet per instal capit chang revenu per revenu per unit research revenu per research chang recogn revenu per research sampl per unit per includ month valid new instal saphyr placement new saphyr research capit number chip revenu research sampl placement revenu research portion placement capit revenu per instal capit placement revenu research revenu growth research bngo outperform
view partnership central bngo busi model expect
compani reli primari intern resourc product develop us
term agreement return licens patent bngo oblig
pay princeton univers mid-single-digit royalti sale relat product
low-single-digit percentag revenu servic cover licens agreement
addit bngo oblig make minimum annual licens mainten fee
total increas annual
bngo agreement genom requir purchas certain
compon use ivd kit instrument chines market
respons manufactur finish system well obtain regulatori
approv china requir purchas certain undisclos minimum number
instrument annual account bngo revenu
view bngo patent describ method non-sequenc base analysi
macromolecul nucleic acid core asset compani import
barrier entri addit compani issu file patent applic
describ variou applic technolog includ optim elong high-
molecular weight nucleid acid genom structur analysi de novo analysi
genom repeat readili obtain current sequencing-bas approach
take view technic know grow bodi clinic data primari
barrier entri patent attorney bngo ip estat appear offer
robust secondari barrier entri like prevent anoth compani directli
replic technic specif saphyr
total bngo global patent portfolio includ issu patent across
licens princeton univers overview provid exhibit
exhibit issu pend patent
bngo reli singl third-parti vendor assembl saphyr separ singl
sourc vendor produc chip consum instrument vendor as-ord
basi maintain inventori finish system bngo may requir
purchas certain compon held vendor inventori greater day
chip manufactur also as-ord contract bngo qualifi second
sourc chip product bngo plan maintain capac assembl reagent kit
sourc reagent enzym substrat third parti
commerci focusnumb issu pend patentsnanochannel devic macromolecul analysi use nanochannel array genet detect copi number analysi genom sequenc epigenom analysi isol process use nanochannel analysi optim nanochannel analysi product bionano genom
manag believ compon part saphyr purchas multipl
supplier new product develop design prototyp produc
compani headquart san diego leas bngo san diego facil expir
take would like see compani invest second sourc supplier
system reduc risk suppli disrupt normal busi condit current
infrastructur appear adequ support demand
sale distribut
compani sell saphyr us direct sale forc six rep call
primarili research lab financi forecast call bngo expand sale forc
rep gradual transit portion current rep research account
take go-to market strategi cytogenet lab like clinic data-driven
sell focus init lab affili lead cancer center expand
commerci cancer test lab believ bngo current sale forc adequ
bngo reli distributor sell saphyr asia intern market exhibit
collect relationship import compani revenu
growth academ research market sale custom
outsid us revenu splt roughli europ asia
take distribut relationship adequ support ex us adopt academ
research market expand reimburs eventu support ex-u clinic sale
cytogenet clinic indic believ compani may need transit
jv partner model support clinician educ broad adopt
model call bngo achiev profit decemb
compani feder tax asset howev expect asset
impair part full april financ transact like classifi
chang control view expect futur oper loss
avail off-set first three year futur profit
take expect compani begin pay tax stautaturi rate
companyregion whitehead scientif ltdafricabiosens srlcentral eastern europeaccela central eastern europeberri genomicsmainland chinastar research technologymainland chinagen companyexclus hong kong macauultravis technologymainland chinaa one corporationjapansciencewerkesingapor malaysia indonesia molecular diagnost koreasouth koreagendiscoveri inc taiwan bngo outperform
uniqu code issu use optic imag perform cytogent analysi
expect lab file miscellan code follow addit public
introduct ldt lab may file potenti clinician begin
use code expect price crosswalk fsh test
reimburs fsh test per probe probe per assay
rang median around
view bngo histor financi offer limit transpar predict futur
financi perform due potenti significantli differ annual dispos chip
pull analyz instal clinic cytogenet lab prior instal
academ research facil potenti significantli higher sell infrastructur
requir gain market share clinic test market limit disclosur
